Emerging cancer therapies and cardiovascular risk
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Thrombosis and Thrombolysis"
DOI: 10.1007/s11239-020-02263-9
Abstract: The cardiovascular (CV) toxicity profiles of traditional cancer therapies such as anthracyclines and radiation therapy are familiar to many cardiologists. With the development and widespread use of additional cancer therapeutics, CV toxicities related to these… read more here.
Keywords: emerging cancer; cardiovascular risk; cancer; cancer therapies ... See more keywords
TRPV2 channel-based therapies in the cardiovascular field. Molecular underpinnings of clinically relevant therapies.
Sign Up to like & getrecommendations! Published in 2020 at "Progress in biophysics and molecular biology"
DOI: 10.1016/j.pbiomolbio.2020.06.001
Abstract: The transient receptor potential (TRP) ion channel family is composed of twenty-seven channel proteins that are ubiquitously expressed in the human body. The TRPV (vanilloid) subfamily has been a recent target of investigation within the… read more here.
Keywords: based therapies; channel based; trpv2 channel; therapies cardiovascular ... See more keywords
A Clinical Perspective of Anti-Fibrotic Therapies for Cardiovascular Disease
Sign Up to like & getrecommendations! Published in 2017 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2017.00186
Abstract: Cardiac fibrosis are central to various cardiovascular diseases. Research on the mechanisms and therapeutic targets for cardiac fibrosis has advanced greatly in recent years. However, while many anti-fibrotic treatments have been studied in animal models… read more here.
Keywords: anti fibrotic; fibrosis; fibrotic therapies; therapies cardiovascular ... See more keywords